Opinion|Videos|July 29, 2024
Current Approach for Treating Anemia in LR-MDS
Author(s)Guillermo Garcia-Manero, MD
A medical oncologist outlines approaches to treating anemia in patients with lower-risk myelodysplastic syndromes.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is your current approach for treating anemia in LR-MDS?
- When would you choose ESAs for first-line treatment?
- When would you switch therapies? Would you dose escalate before switching to an EMA (e.g. second-line)?
- What factors lead to a decision to use luspatercept as a first-line treatment?
- When do you dose escalate?
- When do you dose escalate?
- When would you choose ESAs for first-line treatment?
Advertisement
Related to this article
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Late-Breaking Phase 3 Data Headline ESMO 2026 Presidential Symposium I
2
ESMO 2026 Presidential Symposium II Showcases OS-Improving LBAs in Lung and GI Cancers
3
Key Takeaways From DeLLphi-305 at ESMO 2026
4
Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC
5